Sarepta Therapeutics (SRPT) News Today $73.61 -2.72 (-3.56%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$73.88 +0.27 (+0.36%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTMarch 25 at 10:00 AM | prnewswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lifted by Emerald Advisers LLCEmerald Advisers LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,242 shares of the biotechnology compMarch 25 at 5:37 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Signaturefd LLCSignaturefd LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 91.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 690 shares of the biotechnology company's stock after selliMarch 25 at 3:53 AM | marketbeat.comSimplify Asset Management Inc. Cuts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Simplify Asset Management Inc. reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 83.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,779 shares of the biotechnMarch 24 at 6:18 AM | marketbeat.comIs This Stock a Buy After a Massive 20% Drop in 1 Day?March 23 at 9:30 AM | fool.comScotiabank Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $80.00March 23 at 1:52 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst DowngradeMarch 22, 2025 | americanbankingnews.com2SRPT : This Is What Whales Are Betting On Sarepta TherapeuticsMarch 21, 2025 | benzinga.comScotiabank Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $80.00Scotiabank decreased their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday.March 21, 2025 | marketbeat.comBiotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & MoreMarch 21, 2025 | finance.yahoo.comWhy Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?March 21, 2025 | msn.comSarepta Therapeutics (SRPT) Receives a Buy from Evercore ISIMarch 21, 2025 | markets.businessinsider.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% on Analyst DowngradeSarepta Therapeutics (NASDAQ:SRPT) Trading Down 4% on Analyst DowngradeMarch 21, 2025 | marketbeat.comTraders Buy Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)March 21, 2025 | americanbankingnews.comSarepta: Should Investors Run For The Exit?March 20, 2025 | seekingalpha.comSarepta Therapeutics (NASDAQ:SRPT) Sees Large Volume Increase - Should You Buy?Sarepta Therapeutics (NASDAQ:SRPT) Sees Large Volume Increase - What's Next?March 20, 2025 | marketbeat.comInvestors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) saw some unusual options trading activity on Wednesday. Stock investors acquired 1,796 call options on the company. This represents an increase of approximately 15% compared to the typical daily volume of 1,556 call options.March 20, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday.March 20, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC WainwrightHC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday.March 20, 2025 | marketbeat.comThrivent Financial for Lutherans Buys 14,444 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Thrivent Financial for Lutherans boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 639,332 shares of the bMarch 20, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $99.00 by Analysts at Deutsche Bank AktiengesellschaftMarch 20, 2025 | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Sarepta Therapeutics (NASDAQ:SRPT)March 20, 2025 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $170.41 Consensus Target Price from BrokeragesMarch 20, 2025 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $170.41 Average Price Target from AnalystsShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-three brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hMarch 20, 2025 | marketbeat.comSarepta price target lowered to $99 from $124 at Deutsche BankMarch 19, 2025 | markets.businessinsider.comSarepta Therapeutics (SRPT) Gets a Hold from ScotiabankMarch 19, 2025 | markets.businessinsider.comSarepta Therapeutics' (SRPT) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday.March 19, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Here's WhySarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Should You Sell?March 19, 2025 | marketbeat.comPatient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)March 19, 2025 | tipranks.comSarepta Therapeutics' (SRPT) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday.March 19, 2025 | marketbeat.comGene-Therapy Maker Sarepta Tanks After Patient DeathMarch 19, 2025 | wsj.comSarepta falls after notifying of patient death following treatment with ElevidysMarch 19, 2025 | markets.businessinsider.comSarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.March 19, 2025 | msn.comCantor Fitzgerald Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)March 18, 2025 | markets.businessinsider.comAnalysts remain optimistic about Elevidys after Sarepta reports patient deathMarch 18, 2025 | markets.businessinsider.comSarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmMarch 18, 2025 | gurufocus.comSarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmMarch 18, 2025 | globenewswire.comSarepta: Disclosure Of An Elevidys Patient's Death Creates Market UncertaintyMarch 18, 2025 | seekingalpha.comSarepta safety update on Elevidys boosts Regenxbio, hurts Solid BioMarch 18, 2025 | msn.comWhy Sarepta Therapeutics (SRPT) Shares Are Sliding TodayMarch 18, 2025 | msn.comSarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug DiesMarch 18, 2025 | msn.comPatient dies following muscular dystrophy gene therapy, Sarepta reportsMarch 18, 2025 | financialpost.comPatient dies following muscular dystrophy gene therapy, Sarepta reportsMarch 18, 2025 | financialpost.comSarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient deathMarch 18, 2025 | proactiveinvestors.comSarepta Therapeutics Hits 52-Week Low After Patient DeathMarch 18, 2025 | marketwatch.comSarepta stock tumbles on patient death newsMarch 18, 2025 | investing.comSarepta discloses patient death after gene therapy treatmentMarch 18, 2025 | msn.comSarepta Therapeutics’ stock falls after patient dies of liver failureMarch 18, 2025 | marketwatch.comSarepta plunges after death linked to ElevidysMarch 18, 2025 | msn.comSarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock PlungesMarch 18, 2025 | benzinga.com Remove Ads Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼-0.070.71▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼3811▲SRPT Articles Average Week Remove Ads Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
